A perspective on anti-EGFR therapies targeting triple-negative breast cancer
about
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast CancerPotential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast CancerIdentification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line.Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway.One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells.Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming.Photo-immobilized EGF chemical gradients differentially impact breast cancer cell invasion and drug response in defined 3D hydrogels.PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.Immune Landscape of Breast Cancers.Addressing the challenges of applying precision oncology.Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities
P2860
Q38373249-769885A3-9B2B-4A63-9FE9-2059E5CCE7D9Q38640378-D48CAFA9-D95A-43E0-939F-79AD3A850CA9Q38844554-0BB94831-05DF-404C-84E7-F976147065B4Q39028181-F6462D1B-16BA-4277-A90F-6127F90E363BQ39113994-1E62EC03-119B-4B1B-A70F-94C6F56DBC5CQ40953806-CF7DE97C-1A98-4356-8BA3-85AA8BEF6A54Q41661268-DF06CB9B-D6F5-4A1A-9534-054935546A63Q42318005-07C41DEA-6156-4B21-9E1E-232B60765FB5Q42513445-2690A0AC-9606-417D-A119-936F1EB0CAABQ47242275-45D269ED-4185-4811-B5B7-80729A22EBB2Q48134167-D613A5AB-C3F4-4C6B-B2F6-031332B5DFA6Q49918151-8DB14458-80C2-4FE5-9749-EB3E8453DDF5Q52647698-05763E1B-91FA-4E42-8E08-126F9D7FAABCQ54965602-527A936F-3E89-4344-9629-A7075B720969Q54978331-8CCC0EF5-EA07-43A4-985A-D3C4F5276D1DQ55029136-9E1261E6-D1BE-4AD4-9E13-2F6E78FAA310Q55032160-CC85D049-B4DE-4D3A-973A-A7C898D3AC0FQ55314165-9085E2C0-AC4E-4C32-9B0D-0E006C94D8F5Q55360028-2AFCB661-0FDB-4256-AFBB-38EB8B62D7BEQ55513349-566767CB-32AF-490A-9AE9-5BEF53B5AA65Q58707066-0C6303BA-E899-4162-A8C0-E66330DE36D3
P2860
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@ast
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@en
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@nl
type
label
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@ast
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@en
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@nl
prefLabel
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@ast
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@en
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@nl
P2093
P2860
P1476
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
@en
P2093
P2860
P304
P407
P577
2016-08-01T00:00:00Z